Outset Medical and US Renal Care have announced via press release a multi-year agreement to help accelerate home haemodialysis in the USA.
According to their announcement, studies have shown that patients with end-stage kidney disease (ESKD) are healthier both mentally and physically when completing dialysis at home. They also state that they are more likely to be employed and maintain more control of their daily activities.
Despite this, the press release states that only 3% of the US ESKD population currently performs home haemodialysis, in large part, they claim, due to historically complicated systems that made it “too difficult to undertake or sustain”. Under their multi-year agreement, US Renal Care can utilise Outset’s Tablo haemodialysis system as a home dialysis option throughout the 33 states in which it provides care. Patients dialysing with Tablo report that the system is easy to learn and operate in their home, according to Outset and US Renal Care. The companies hope that by expanding treatment options in the communities served by US Renal Care, they will be able to aid in meeting the growing demand of dialysis patients seeking treatment at home.
Tablo, which is indicated for use in both a hospital setting and at home, represents a significant technological advancement that transforms the dialysis experience for patients and operationally simplifies it for providers, according to the press release. The system requires access to tap water and a standard electrical outlet and can serve as a single enterprise solution that can be utilised “across the continuum of care”, as Outset frame it, allowing dialysis to be delivered anytime, anywhere and by anyone.
Commenting on the announcement, Leslie Trigg, chair and chief executive officer (CEO) of Outset Medical, stated: “Our collaboration with US Renal Care is an important step forward in providing dialysis patients with options for where, when and how they want to dialyse. Tablo was specifically designed to reduce the complexity of dialysis and help restore the identity and agency of patients who must dialyse to survive. We are pleased to partner with US Renal Care to advance this mission.”
Adding his thoughts, co-CEO at US Renal Care, Steve Nottingham, said: “We strive to provide patients with new and innovative solutions that deliver the best outcomes possible. We have seen success using the Tablo system in our home haemodialysis programme, and with our multi-year agreement with Outset, can continue providing our patients and caregivers access to lifesaving dialysis treatment in an easy-to-operate system, all in the comfort of their own homes.”
